A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

Paolo Strati, Loretta J. Nastoupil, Richard E. Davis, Luis E. Fayad, Nathan Fowler, Fredrick B. Hagemeister, Larry Kwak, Yasuhiro Oki, Michael Wang, Jason Westin, Charnelle E. Ruben, Emily T. Wesson, Richard Piekarz, Michelle A. Fanale, Hun Ju Lee

Research output: Contribution to journalLetter

3 Scopus citations
Original languageEnglish (US)
Pages (from-to)E26-E28
Issue number1
StatePublished - 2020

ASJC Scopus subject areas

  • Hematology

Cite this